NASDAQ:CNTX Context Therapeutics Q4 2023 Earnings Report $1.34 0.00 (0.00%) As of 10:40 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Context Therapeutics EPS ResultsActual EPS-$0.42Consensus EPS -$0.35Beat/MissMissed by -$0.07One Year Ago EPSN/AContext Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AContext Therapeutics Announcement DetailsQuarterQ4 2023Date3/21/2024TimeN/AConference Call DateThursday, March 21, 2024Conference Call Time8:00AM ETUpcoming EarningsContext Therapeutics' Q3 2025 earnings is scheduled for Wednesday, November 5, 2025, with a conference call scheduled at 12:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2025 Earnings ReportConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Context Therapeutics Earnings HeadlinesContext Therapeutics to Present New Data on Two Bispecific T Cell Engagers at SITC 2025October 12, 2025 | msn.comInstitutions profited after Context Therapeutics Inc.'s (NASDAQ:CNTX) market cap rose US$14m last week but private equity firms profited the mostOctober 9, 2025 | uk.finance.yahoo.comOptions Pro Reveals His #1 Retirement Income TradeIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading strategy that could help accelerate your retirement goals. It’s called the Retirement Trade — a short-term approach designed to capture consistent morning setups without waiting months for results.October 16 at 2:00 AM | Base Camp Trading (Ad)Context Therapeutics Inc. (NASDAQ:CNTX) Receives $5.20 Average Price Target from BrokeragesOctober 7, 2025 | americanbankingnews.comContext Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual MeetingOctober 6, 2025 | finance.yahoo.comContext Therapeutics Inc. to Present Trial Progress and Preclinical Data at SITC 2025 Annual MeetingOctober 6, 2025 | quiverquant.comQSee More Context Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Context Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Context Therapeutics and other key companies, straight to your email. Email Address About Context TherapeuticsContext Therapeutics (NASDAQ:CNTX) (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors. With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies. The company’s development strategy integrates translational science, rigorous patient selection and adaptive trial design, aiming to streamline pathways to regulatory review. Through these efforts, Context Therapeutics seeks to establish proof of concept across multiple indications before pursuing broader commercialization alliances. Headquartered in the United States, Context Therapeutics conducts its clinical research primarily in North America while laying the groundwork for potential global expansion. The company’s leadership team combines industry veterans in drug development with specialists in oncology and translational medicine. Together, they guide Context Therapeutics as it advances novel candidates through clinical milestones, with the goal of delivering targeted treatment options to patients with high unmet medical need.View Context Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Congress Is Buying Intuitive Surgical Ahead of Earnings3 Reasons to Buy Sprouts Farmers Market Ahead of EarningsTesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff Concerns Upcoming Earnings HDFC Bank (10/17/2025)Truist Financial (10/17/2025)American Express (10/17/2025)Nasdaq (10/21/2025)Texas Instruments (10/21/2025)Intuitive Surgical (10/21/2025)Netflix (10/21/2025)Verizon Communications (10/21/2025)General Motors (10/21/2025)CocaCola (10/21/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
